Cause-specific mortality rate of ovarian cancer in the presence of competing risks of death: a nationwide population-based cohort study

• Published in: Journal of gynecologic oncology Vol. 33; no. 1; p. e5
• Main Authors: Shim, Seung-Hyuk, Lim, Myong Cheol, Lee, Dahhay, Won, Young-Joo, Ha, Hyeong In, Chang, Ha Kyun, Cho, Hyunsoon
• Format: Journal Article
• Language: English
• Published: Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 01-01-2022; 대한부인종양학회
• Subjects: Aged; Carcinoma, Ovarian Epithelial; Cause of Death; Cohort Studies; Female; Humans; Incidence; Original; Ovarian Neoplasms; 산부인과학; Ovarian Cancer; Elderly; Survival; Mortality; Cause of Death
• ISSN: 2005-0380; 2005-0399
• DOI: 10.3802/JGO.2022.33.E5

This nationwide cohort study aimed to evaluate the cause-specific mortality (probability of death by ovarian cancer, probability of death by other causes) under the competing risks of death in women with ovarian cancer.
The Korea Central Cancer Registry was searched to identify women with primary ovarian cancer diagnosed between 2006 and 2016. Epithelial ovarian cancer cases were identified using the International Classification of Diseases for Oncology 3rd edition. We estimated the cause-specific mortality according to age (<65 years, ≥65 years), stage (local, regional, and distant), and histology (serous, mucinous, endometrioid, clear cell, and others) under the competing risks framework; moreover, cumulative incidences were estimated.
We included 21,446 cases. Cause-specific mortality continuously increased throughout 10 year follow-up. Compared with women aged <65 years, ovarian cancer-specific mortality (5-year, 28.9% vs. 61.9%; 10-year, 39.0% vs. 68.6%, p<0.001) and other cause mortality (5-year, 1.7% vs. 4.8%; 10-year, 2.8% vs. 8.2%, p<0.001) increased in women aged ≥65 years. This trend was consistent across all the stages and histological types. There was a substantial increase in competing risks from 1.1% in women aged <65 years to 8.0% in women aged ≥65 years in patients with early-stage (p<0.001) non-serous ovarian cancer (p<0.001).
Older age at diagnosis is associated with increasing ovarian cancer-specific mortality and competing risks. Given the substantial effect of competing risks on elderly patients, there is a need for assessment tools to balance the beneficial and harmful effects to provide optimal treatment.